Indium-111 labeled gold nanoparticles for in-vivo molecular targeting.
The present report describes the synthesis and biological evaluation of a molecular imaging platform based on gold nanoparticles directly labeled with indium-111. The direct labeling approach facilitated radiolabeling with high activities while maintaining excellent stability within the biological environment. The resulting imaging platform exhibited low interference of the radiolabel with targeting molecules, which is highly desirable for in-vivo probe tracking and molecular targeted tumor imaging. The indium-111 labeled gold nanoparticles were synthesized using a simple procedure that allowed stable labeling of the nanoparticle core with various indium-111 activities. Subsequent surface modification of the particle cores with RGD-based ligands at various densities allowed for molecular targeting of the αvß3 integrin in-vitro and for molecular targeted imaging in human melanoma and glioblastoma models in-vivo. The results demonstrate the vast potential of direct labeling with radioisotopes for tracking gold nanoparticles within biological systems.
Institute of Nuclear Medicine, University Hospital Bern, Bern 3010-CH, Switzerland; Department of Clinical Research, University Bern, Bern 3010-CH, Switzerland.
Quinn K T
QK
Ng
Institute of Nuclear Medicine, University Hospital Bern, Bern 3010-CH, Switzerland; Department of Clinical Research, University Bern, Bern 3010-CH, Switzerland.
Cristina I
CI
Olariu
Institute of Nuclear Medicine, University Hospital Bern, Bern 3010-CH, Switzerland.
Marcus
M
Yaffee
Institute of Nuclear Medicine, University Hospital Bern, Bern 3010-CH, Switzerland; Department of Clinical Research, University Bern, Bern 3010-CH, Switzerland.
Vincent F
VF
Taelman
Institute of Nuclear Medicine, University Hospital Bern, Bern 3010-CH, Switzerland.
Nicolas
N
Marincek
Institute of Nuclear Medicine, University Hospital Bern, Bern 3010-CH, Switzerland; Department of Clinical Research, University Bern, Bern 3010-CH, Switzerland.
Thomas
T
Krause
Institute of Nuclear Medicine, University Hospital Bern, Bern 3010-CH, Switzerland; Department of Clinical Research, University Bern, Bern 3010-CH, Switzerland.
Lorenz
L
Meier
Institute of Nuclear Medicine, University Hospital Bern, Bern 3010-CH, Switzerland; Department of Clinical Research, University Bern, Bern 3010-CH, Switzerland; Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095-1722, USA. Electronic address: m.a.walter@gmx.net.
Martin A
MA
Walter
D045744:Cell Line, Tumor; D016503:Drug Delivery Systems / Q000379:methods; D005240:Feasibility Studies; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007204:Indium; D039302:Integrin alphaVbeta3 / Q000378:metabolism; D053768:Metal Nanoparticles / Q000737:chemistry*; D057054:Molecular Imaging; D011868:Radioisotopes
D039302:Integrin alphaVbeta3; D011868:Radioisotopes; D007204:Indium
Molecular imaging; Nanomedicine; RGD; cell tracking; α(v)ß(3) integrin